rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Chandler Robinson

Chief Executive Officer

Company insider

Files Form 4 as: Chief Executive Officer, Monopar Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
126
Buys
0
Sells
2
Bought
$0
Sold
$5.8M
Companies
1
Companies where not an officer
0
First trade
9 Aug 2018
Last trade
30 Sep 2026
Last filed
2 Oct 2026

Companies traded

Where they are an officer
MNPR Monopar TherapeuticsDirector, Officer, 10% owner · Biotechnology · last 30 Sep 20260 buys · 2 sells

Activity over time

1 Jul 2025 – 1 Oct 2026
10Jul 25Nov 25Mar 26Jun 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
30 Sep 2026filed 2 Oct 2026MNPR Monopar TherapeuticsBiotechnologySEC FORM 4 Code M—9,801filing
30 Sep 2026filed 2 Oct 2026MNPR Monopar TherapeuticsBiotechnologySEC FORM 4 Code F$346K4,344 at $79.67filing
30 Sep 2026filed 2 Oct 2026MNPR Monopar Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—9,801 at $0.00filing
24 Sep 2026filed 28 Sep 2026MNPR Monopar TherapeuticsBiotechnologySEC FORM 4 Code M$422K14,056 at $30.00filing
24 Sep 2026filed 28 Sep 2026MNPR Monopar TherapeuticsBiotechnologySEC FORM 4 Code M$210K15,000 at $14.00filing
24 Sep 2026filed 28 Sep 2026MNPR Monopar TherapeuticsBiotechnologySEC FORM 4 Sold$911K10,450 at $87.15filing
24 Sep 2026filed 28 Sep 2026MNPR Monopar Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—14,056 at $0.00filing
24 Sep 2026filed 28 Sep 2026MNPR Monopar Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—15,000 at $0.00filing
24 Sep 2026filed 28 Sep 2026MNPR Monopar TherapeuticsBiotechnologySEC FORM 4 Sold$848K9,638 at $87.96filing
24 Sep 2026filed 28 Sep 2026MNPR Monopar TherapeuticsBiotechnologySEC FORM 4 Sold$745K8,368 at $88.97filing
24 Sep 2026filed 28 Sep 2026MNPR Monopar TherapeuticsBiotechnologySEC FORM 4 Sold$54K600 at $89.79filing
24 Sep 2026filed 28 Sep 2026MNPR Monopar Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—14,056 at $0.00filing
24 Sep 2026filed 28 Sep 2026MNPR Monopar Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—15,000 at $0.00filing
24 Sep 2026filed 28 Sep 2026MNPR Monopar TherapeuticsBiotechnologySEC FORM 4 Code M$422K14,056 at $30.00filing
24 Sep 2026filed 28 Sep 2026MNPR Monopar TherapeuticsBiotechnologySEC FORM 4 Code M$210K15,000 at $14.00filing
24 Sep 2026filed 28 Sep 2026MNPR Monopar TherapeuticsBiotechnologySEC FORM 4 Sold$911K10,450 at $87.15filing
24 Sep 2026filed 28 Sep 2026MNPR Monopar TherapeuticsBiotechnologySEC FORM 4 Sold$848K9,638 at $87.96filing
24 Sep 2026filed 28 Sep 2026MNPR Monopar TherapeuticsBiotechnologySEC FORM 4 Sold$745K8,368 at $88.97filing
24 Sep 2026filed 28 Sep 2026MNPR Monopar TherapeuticsBiotechnologySEC FORM 4 Sold$54K600 at $89.79filing
30 Jun 2026filed 2 Jul 2026MNPR Monopar TherapeuticsBiotechnologySEC FORM 4 Code M—12,873filing

News

Monopar Therapeutics (NASDAQ:MNPR) Stock: Insider Chandler Robinson Sells 29,056 Sharesthemarketsdaily.com · 29 Sep 2026

1 headline in the last 90 days name Chandler Robinson; 0 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.

Sectors

Health Care2

Buys in green, sells in red, by the company’s sector.

Related people

Christopher M. StarrDirector · Director at Monopar Therapeutics, filing Form 4 there in the last year
Quan Anh VuChief Financial Officer · Chief Financial Officer at Monopar Therapeutics, filing Form 4 there in the last year
Andrew CittadineChief Operating Officer · Chief Operating Officer at Monopar Therapeutics, filing Form 4 there in the last year
Kim R. TsuchimotoDirector · Director at Monopar Therapeutics, filing Form 4 there in the last year
Raymond AndersonDirector · Director at Monopar Therapeutics, filing Form 4 there in the last year
Patrice RiouxOther role · Also traded MNPR in the last 90 days